Get the Stockscreener App
1.035
2.83%
-0.025
Pyxis Oncology Inc stock is traded at $1.035, with a volume of 34,406.
It is down -2.83% in the last 24 hours and down -11.21% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$1.06
Open:
$1.03
24h Volume:
34,406
Relative Volume:
0.07
Market Cap:
$63.81M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-0.5625
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
-6.36%
1M Performance:
-11.21%
6M Performance:
-18.90%
1Y Performance:
-68.69%
1-Day Range:
$1.02
$1.04
1-Week Range:
$1.00
$1.14
52-Week Range:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.03 | 65.05M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.83 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.13 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.52 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.97 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.45 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Statistical indicators supporting Pyxis Oncology Inc.’s strengthSafe Entry Strategy with High Win Rate - Newser
Can Pyxis Oncology Inc. recover in the next quarterFree Growth Based Stock Signal Screener - Newser
Pyxis Oncology Inc. stock prediction for this weekShort-Term Trade Setup with Forecast Insight - Newser
Pyxis Oncology PYXS 2025Q2 Earnings Preview Downside Concerns Amid Revenue Uncertainty - AInvest
Why Pyxis Oncology Inc. stock attracts strong analyst attentionFree Triple Digit Growth Focused Trade Plan - Newser
Will Pyxis Oncology Inc. outperform the marketFree Real Trader Watchlist of Hot Stocks - Newser
Real time scanner hits for Pyxis Oncology Inc. explainedBuy Strategy Review With Performance Summary - Newser
Earnings visualization tools for Pyxis Oncology Inc.Daily Technical Forecast for Quick Gains - Newser
AI Trend Models Suggest Bounce for Pyxis Oncology Inc.Early Entry Picks Before News Breakout Reviewed - beatles.ru
Pyxis Oncology Inc. stock chart pattern explainedSector Rotation Outlook With Historical Summary - Newser
Custom strategy builders for tracking Pyxis Oncology Inc.Trading Opportunities Forecast by AI Insight - Newser
Visual analytics tools that track Pyxis Oncology Inc. performanceFree Risk Managed Intraday Trade Alerts - Newser
How Pyxis Oncology Inc. stock performs during market volatilityGrowth Projection Summary for Long-Term Investors - Newser
Should you hold or exit Pyxis Oncology Inc. nowPrice Spike Prediction for Active Traders - Newser
Pyxis Oncology shares rise 4.36% after-hours after announcing revisions to patient enrollment for Phase 1 clinical trial. - AInvest
Pyxis Oncology Updates Phase 1 Trial Enrollment: What You Need to Know - AInvest
Pyxis Oncology updates patient enrollment for Phase 1 trial of micvotabart pelidotin - Investing.com
Pyxis Oncology Updates Phase 1 Trial Enrollment - TipRanks
How to integrate Pyxis Oncology Inc. into portfolio analysis toolsImmediate Entry Point Prediction Strategy - Newser
How does Pyxis Oncology Inc. compare to its industry peersBreakthrough capital growth - Jammu Links News
What are analysts’ price targets for Pyxis Oncology Inc. in the next 12 monthsBreakthrough capital growth - Jammu Links News
What are the technical indicators suggesting about Pyxis Oncology Inc.Unlock daily trading alerts for profits - Jammu Links News
Should I hold or sell Pyxis Oncology Inc. stock in 2025Outstanding capital returns - Jammu Links News
What makes Pyxis Oncology Inc. stock price move sharplyDynamic profit opportunities - Jammu Links News
Pyxis Oncology Inc. Stock Analysis and ForecastBuild capital through low-risk investments - Jammu Links News
What institutional investors are buying Pyxis Oncology Inc. stockFastest return on investment - Jammu Links News
What is Pyxis Oncology Inc. company’s growth strategyInvest smarter with expert stock picks - Jammu Links News
We Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth Carefully - uk.finance.yahoo.com
Pyxis Oncology Inc. Consolidation Zone May Signal AccumulationLow Capital High Return Stock Plans Reviewed - metal.it
What high frequency data says about Pyxis Oncology Inc.Weekly Watchlist of High Movers Released - metal.it
Live Scanner Shows Breakout on Pyxis Oncology Inc.Stock Selection With High Accuracy Based on Models - metal.it
Risk adjusted return profile for Pyxis Oncology Inc. analyzedSmart Trade Forecast Based on Neural Logic - Newser
Bullish Candlestick Pattern Forms in Pyxis Oncology Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
Chartists See Breakout Potential in Pyxis Oncology Inc.Growth Focused Entry Plan Suggestions Issued - metal.it
How did PYXS's revenue and expenses trend in Q4 2024? - AInvest
Price action breakdown for Pyxis Oncology Inc.Stable Entry High Return Opportunities in Focus - metal.it
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):